IraqTuberculosis profile
Population  2015 36 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.86 (0.018–3.3) 2.4 (0.05–8.9)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.02)
Incidence  (includes HIV+TB) 16 (14–18) 43 (38–49)
Incidence (HIV+TB only) 0.016 (0.012–0.02) 0.04 (0.03–0.05)
Incidence (MDR/RR-TB)** 1.2 (0.88–1.5) 3.3 (2.4–4.1)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 1 (0.7–1.3) 7.1 (5.8–8.4) 8.1 (6.5–9.8)
Males 0.81 (0.57–1) 6.8 (5.3–8.2) 7.6 (5.9–9.3)
Total 1.8 (1.4–2.2) 14 (13–15) 16 (14–18)
TB case notifications, 2015  
Total cases notified 8 255
Total new and relapse 8 183
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 51%
          - % pulmonary 61%
          - % bacteriologically confirmed among pulmonary 59%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 52% (46–59)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0–0.21)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 0 0%
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  400
(310–490)
Estimated % of TB cases with MDR/RR-TB 6.1% (4.4–7.8) 24% (16–32)  
% notified tested for rifampicin resistance 1% 25% 279
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 93, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 73, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 92% 8 268
Previously treated cases, excluding relapse, registered in 2014 79% 73
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013 58% 84
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 26
Funding source: 58% domestic, 42% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data